The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Perstarium     (2S,3aS,7aS)-1-[(2R)-2- [[(1S)-1...

Synonyms: Pirindopril, SureCN682285, McN-A 2833, LS-82762, BRN 4300272, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PERINDOPRIL

  • Adverse event with first-dose perindopril in congestive heart failure [1].
  • Blood pressure, forearm arterial hemodynamics (with a pulsed Doppler flowmeter), and echocardiographic parameters were studied in 16 patients with sustained essential hypertension before and 3 months after administration of the converting enzyme inhibitor perindopril [2].
  • Treatment of DS rats with the CEI perindopril (4.56 mg x kg(-1) x d(-1)) did not affect SBP (225+/-6 mm Hg) but modestly improved EDR (ED50: 6.07+/-.37; P<.05 versus hypertensive DS) as well as proteinuria and glomerular histology [3].
  • METHODS AND RESULTS: Sixteen patients with ischemic heart disease were treated either with perindopril (4 mg/d PO) for up to 36 days before surgery (n = 9) or without the inhibitor as control subjects (n = 7) [4].
  • The aim of the present study was to examine the in vivo effect of candesartan (CA), a clinically used AT(1)-R blocker (ARB), and perindopril (PE), an angiotensin-converting enzyme (ACE) inhibitor (ACE-I), on pig serum-induced liver fibrosis development in rats [5].

Psychiatry related information on PERINDOPRIL


High impact information on PERINDOPRIL

  • Perindopril completely abolished the biosynthesis of PDGF-AB but had little effect on residual FGF-2 [9].
  • CONCLUSIONS: The ability of ACE inhibitors such as perindopril to attenuate neointima formation and growth in balloon catheter-injured rat carotid arteries is dependent on early events in the media, the inhibition of SMC PDGF-AB biosynthesis and attenuation of proliferation [9].
  • In the internal mammary artery, free ACE was similarly inhibited by perindopril in the endothelium (P < .05) and adventitia (P < .05), and the free ACE-to-total ACE ratio, an index of ACE inhibition, was markedly decreased by perindopril in parallel in the endothelium (P < .001) and adventitia (P < .001) [4].
  • These results indicate that perindopril effectively penetrates the vascular wall to inhibit ACE in the adventitia, thus providing evidence that perindopril may be beneficial in inhibiting both circulating Ang II and its local formation in the vascular wall [4].
  • The present study was undertaken to assess the sites and extent of in vivo inhibition of ACE by long-term perindopril treatment in different layers of the internal mammary artery in patients with ischemic heart disease [4].

Chemical compound and disease context of PERINDOPRIL


Biological context of PERINDOPRIL


Anatomical context of PERINDOPRIL


Associations of PERINDOPRIL with other chemical compounds


Gene context of PERINDOPRIL


Analytical, diagnostic and therapeutic context of PERINDOPRIL


  1. Adverse event with first-dose perindopril in congestive heart failure. Lees, K.R., Reid, J.L. Lancet (1997) [Pubmed]
  2. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Asmar, R.G., Pannier, B., Santoni, J.P., Laurent, S., London, G.M., Levy, B.I., Safar, M.E. Circulation (1988) [Pubmed]
  3. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Hayakawa, H., Coffee, K., Raij, L. Circulation (1997) [Pubmed]
  4. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Zhuo, J.L., Froomes, P., Casley, D., Liu, J.J., Murone, C., Chai, S.Y., Buxton, B., Mendelsohn, F.A. Circulation (1997) [Pubmed]
  5. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., Fukui, H. Hepatology (2001) [Pubmed]
  6. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Tzourio, C., Anderson, C., Chapman, N., Woodward, M., Neal, B., MacMahon, S., Chalmers, J. Arch. Intern. Med. (2003) [Pubmed]
  7. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Ferrari, R. Arch. Intern. Med. (2006) [Pubmed]
  8. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. Cooper, M.E., Rumble, J.R., Allen, T.J., O'Brien, R.C., Jerums, G., Doyle, A.E. Kidney Int. (1992) [Pubmed]
  9. Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Wong, J., Rauhöft, C., Dilley, R.J., Agrotis, A., Jennings, G.L., Bobik, A. Circulation (1997) [Pubmed]
  10. Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study. Stumpe, K.O., Overlack, A. Am. J. Med. (1992) [Pubmed]
  11. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. Matsumoto, T., Minai, K., Horie, H., Ohira, N., Takashima, H., Tarutani, Y., Yasuda, Y., Ozawa, T., Matsuo, S., Kinoshita, M., Horie, M. J. Am. Coll. Cardiol. (2003) [Pubmed]
  12. Antihypertensive efficacy and safety of perindopril in mild-to-moderate essential hypertension: results of a double-blind multicenter study versus atenolol. Morgan, T.O., Louis, W.J., MacDonald, G.J., Conway, E.L., Bartholomeusz, L.C., Anderson, A.I., Cameron, D.P., Donnelly, T., Frewin, D.B., Hooper, M.J. Am. J. Med. (1992) [Pubmed]
  13. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Davis, B.J., Forbes, J.M., Thomas, M.C., Jerums, G., Burns, W.C., Kawachi, H., Allen, T.J., Cooper, M.E. Diabetologia (2004) [Pubmed]
  14. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Davis, B.J., Johnston, C.I., Burrell, L.M., Burns, W.C., Kubota, E., Cao, Z., Cooper, M.E., Allen, T.J. Diabetologia (2003) [Pubmed]
  15. Importance of cardiac, but not vascular, hypertrophy in the cardiac baroreflex deficit in spontaneously hypertensive and stroke-prone rats. Head, G.A., Minami, N. Am. J. Med. (1992) [Pubmed]
  16. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. Duboc, D., Meune, C., Lerebours, G., Devaux, J.Y., Vaksmann, G., Bécane, H.M. J. Am. Coll. Cardiol. (2005) [Pubmed]
  17. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Charrier, S., Michaud, A., Badaoui, S., Giroux, S., Ezan, E., Sainteny, F., Corvol, P., Vainchenker, W. Blood (2004) [Pubmed]
  18. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Fox, K.M., Henderson, J.R., Bertrand, M.E., Ferrari, R., Remme, W.J., Simoons, M.L. Eur. Heart J. (1998) [Pubmed]
  19. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Bak, J.F., Gerdes, L.U., Sørensen, N.S., Pedersen, O. Am. J. Med. (1992) [Pubmed]
  20. Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension. Jandrain, B., Herbaut, C., Depoorter, J.C., Voorde, K.V. Am. J. Med. (1992) [Pubmed]
  21. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Daly, C.A., Fox, K.M., Remme, W.J., Bertrand, M.E., Ferrari, R., Simoons, M.L. Eur. Heart J. (2005) [Pubmed]
  22. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Thybo, N.K., Stephens, N., Cooper, A., Aalkjaer, C., Heagerty, A.M., Mulvany, M.J. Hypertension (1995) [Pubmed]
  23. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. McLennan, S.V., Kelly, D.J., Cox, A.J., Cao, Z., Lyons, J.G., Yue, D.K., Gilbert, R.E. Diabetologia (2002) [Pubmed]
  24. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Toblli, J.E., Cao, G., DeRosa, G., Di Gennaro, F., Forcada, P. Am. J. Hypertens. (2004) [Pubmed]
  25. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Zhuo, J.L., Mendelsohn, F.A., Ohishi, M. Hypertension (2002) [Pubmed]
  26. Cardiac protective effect of astragalus on viral myocarditis mice: comparison with perindopril. Chen, X.J., Bian, Z.P., Lu, S., Xu, J.D., Gu, C.R., Yang, D., Zhang, J.N. Am. J. Chin. Med. (2006) [Pubmed]
  27. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Gilbert, R.E., Wu, L.L., Kelly, D.J., Cox, A., Wilkinson-Berka, J.L., Johnston, C.I., Cooper, M.E. Am. J. Pathol. (1999) [Pubmed]
  28. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Schwartzkopff, B., Brehm, M., Mundhenke, M., Strauer, B.E. Hypertension (2000) [Pubmed]
WikiGenes - Universities